Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks to Avoid in Biotech

By Sean Williams, Cory Renauer, and Brian Feroldi - Feb 28, 2017 at 10:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.

When investors are right in the biotech industry, it can mean triple-digit percentage gains, or even higher. Unfortunately, the odds are heavily stacked against being correct given that most clinical trials end in failure. 

Keeping in mind that most biotech stocks are losing money (and that they may continue to do so for years to come), we asked three of our healthcare contributors to name one biotech stock they'd strongly encourage investors to avoid. Making the cut were MannKind (MNKD 1.76%), Organovo Holdings (ONVO 2.84%), and Novavax (NVAX 12.49%)

Businessman holding his hands up as if to say, "no thanks."

Image source: Getty Images.

An uphill battle that may never end 

Sean Williams (MannKind): Though it's already lost more than 90% of its market value over the past two years, inhalable diabetes drug developer MannKind is the one company I'd strongly urge investors to keep their distance from in the biotech industry.

On the surface, MannKind looked to have a winning product on its hands with Afrezza, its inhalable diabetes drug for both type 1 and type 2 patients. Afrezza was fast-acting, it metabolized through the body in a more efficient manner than standard insulins on the market, it met its primary endpoint in clinical trials, and it was potentially taking the need for needles out of the equation -- or reducing their need substantially. But what looks good on paper doesn't always work in the business world.

MannKind initially entered into an agreement with Sanofi (NYSE: SNY), thinking it had found a partner for its possible blockbuster drug. Unfortunately, Afrezza hardly got off the ground, and as soon as Sanofi could walk away from the deal (January 2016), it took the chance, taking a hefty charge in the process.

Now MannKind is on its own and looking to market Afrezza. While Sanofi had an entire portfolio of products to tend to, Afrezza is it for MannKind, so it's not surprising that the company has made more progress in the past couple of months than Sanofi did during its licensing tenure. MannKind has managed to get Afrezza approved on the formularies for both Aetna and Express Scripts. Unfortunately, Afrezza's higher price tag could still be an impediment -- as could the time it might take for the company to recover from its cash burn.

MannKind's Afrezza.

Image source: MannKind.

MannKind ended the third quarter with just $35.5 million in cash, $30.1 million in credit access via the Mann Group, and $50 million in at-the-market (ATM) common stock issuances at its disposal. It did receive a $30.6 million payment from Sanofi recently, and $16.7 million from the sale of real estate last week, but even all that combined may not be enough to see MannKind to profitability. After all, we're talking about a drug that struggled to hit $2 million in sales a quarter after its first launch. Plus, with every ATM sale, the value of MannKind's existing shareholders' stakes gets diluted just a little bit more.

With its outlook exceptionally cloudy, I'd urge investors to avoid MannKind.

Too bad you can't print a profit margin

Cory Renauer (Organovo): This bioprinting specialist might be one of the more interesting healthcare companies in business right now, but you might be better off watching the highly volatile stock bounce around from the cheap seats. At recent prices, shares of Organovo are at a sky-high multiple of about 71.3 times the amount of revenue it reported during the past year, despite a recent market beat-down.

Sales have grown quickly in recent quarters, but further hints of a slowdown could lead to heavier losses than investors suffered when the company lowered its forward outlook recently. In February the company reduced its total revenue projections for fiscal 2017 from between $4.5 million and $6.2 million to a range between $3.7 million to $4.5 million.

Organovo employee working in the lab.

Image source: Organovo Holdings.

Organovo's printed kidney and liver tissue has attracted some important attention lately, and now the company boasts 11 of the world's top 25 pharma companies as customers. While its list of customers has grown, their interest in printed human tissues for preclinical new-drug testing appears to be waning.

The company finished 2016 with $70 million in cash and cash equivalents. At its present cash-burn rate, that might be enough to keep the lights on for a couple more years, but ambitious plans could result in a value-diluting share offering even earlier. A plan to develop therapeutic liver tissue will require significant investment in the near term simply to bring such a product into human-stage testing (where things really get expensive).

If you're hungry for exposure to 3D bioprinting, you might be far better off with an investment in Johnson & Johnson. The healthcare giant has forged several collaborations with bioprinting start-ups that could result in products that complement its existing operations, such as printed cartilage for knee replacements. J&J might not be as exciting as an Organovo position, but it's far less likely to lead to steep losses in the long run.

A troubled past

Brian Feroldi (Novavax): Drug development is a risky business, so it is quite common for even the most promising of treatments to fail in spectacular fashion in late-stage trials.

Senior citizen getting a vaccine.

Image source: Getty Images.

That's exactly what happened to Novavax, a clinical-stage biotech focused on vaccines. The company was developing a promising vaccine for respiratory syncytial virus, or RSV, a disease that afflicts about 64 million people around the world each year. While most healthy adults can easily defend themselves against this disease, infants and the elderly tend to be quite vulnerable. In fact, roughly 160,000 people die from RSV each year. That's why investors were so excited about Novavax's RSV F vaccine. If the drug worked, it could have gone on to generate billions for the company and save thousands of lives each year. 

Unfortunately, things didn't exactly go according to plan. RSV F failed to meet its primary endpoints in a phase 3 trial involving adults age 60 or older. The news caused shares to plunge 85% in a single day.

Despite the setback, Novavax hasn't given up hope. It is running another phase 3 trial with the drug aimed at passing immunity on to infants by giving the vaccine to pregnant women. It's also running a phase 2 study to take another swing at treating older adults.

I'm certainly hopeful that these trials will pan out, but I think that chances of failure are quite high. That's why I'd suggest steering clear of Novavax for now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.05 (1.76%) $0.07
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$64.29 (12.49%) $7.14
Organovo Holdings, Inc. Stock Quote
Organovo Holdings, Inc.
ONVO
$1.81 (2.84%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.